Paper 77 - A RANDOMIZED PHASE III TRIAL OF DOXORUBICIN + PEMBROLIZUMAB VERSUS DOXORUBICIN ALONE FOR TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA AND RELATED POORLY DIFFERENTIATED SARCOMAS: ECOG-ACRIN EA7222

Author(s)

• 

  Seth M. Pollack, MD

  Professor with Tenure
  Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Oncology, Chicago
  Chicago, Illinois, United States

  Slides

Co-Author(s)

• OJ

  Opeyemi Jegede, PhD

  Harvard
  Boston, Massachusetts, United States
• CH

  Candace L. Haddox, MD

  Dana Farber Cancer Institute
  Boston, Massachusetts, United States
• MW

  Michael J. Wagner, MD

  Dana-Farber Cancer Institute
  Boston, Massachusetts, United States
• RS

  Ronnie Siebro, MD (he/him/his)

  Professor
  Mayo
  Jacksonville, Florida, United States
• RR

  Richard F. Riedel, MD

  Duke Cancer Institute
  Durham, North Carolina, United States
• KC

  Kenneth Cardona, MD

  Winship Cancer Institute
  Atlanta, Georgia, United States